In brief
As the price of insulin continues to rise, advocates and lawmakers are pushing for the INSULIN Act, which seeks to cap monthly insulin costs at $35 for individuals with private insurance. The bill, backed by bipartisan support, is a response to the increasing financial burden on millions of Americans who depend on this essential medication for survival. Diabetes patients express concerns about long-term affordability and accessibility, emphasizing the struggles faced by younger adults entering the workforce amidst high healthcare costs.
NEW YORK (AP) — For the countless individuals relying on insulin to maintain their health, the financial strain is becoming an emergency. Bain Brandon, a two-year-old with Type 1 diabetes, embodies this struggle as his family grapples with the monthly costs of insulin, which amount to $194. His mother's concern extends beyond today, worrying about future expenses when he will no longer be on their insurance plan.
In light of such challenges, a bipartisan coalition in Congress is advancing the INSULIN Act. This proposed legislation aims to cap insulin prices at $35 per month for those with private insurance and establish pilot programs in states to offer subsidized insulin to the uninsured. This move follows previous efforts that successfully capped insulin prices at $35 for Medicare beneficiaries under the Inflation Reduction Act last year.
Currently, around 8.1 million Americans need insulin, including over two million with Type 1 diabetes. However, the costs can vary dramatically based on insurance status. While some beneficiaries face minimal out-of-pocket expenses, others can end up paying over $300 each month due to a lack of state regulations for self-insured plans.
Major insulin manufacturers, like Eli Lilly and Novo Nordisk, are responding to this crisis with their own affordability programs, but access remains an obstacle for many. Reports indicate that approximately 57% of adults with private insurance are on self-insured plans that evade state regulations, leaving a significant number unable to benefit from recent initiatives.
Despite the overwhelming need for affordability, previous legislative efforts to cap insulin costs have stalled in Congress. Advocates are now pinning their hopes on the INSULIN Act, with diabetes patients expressing that a $35 cap would not only ease their financial burden but also allow them to allocate funds towards essential living costs.
“It’s a balancing act,” said Breana Glover, a Houston resident and Type 1 diabetes patient, who manages her expenses by cutting back on her food intake to stretch her insulin supply. Advocates like Manny Hernandez, CEO of The Diabetes Link, are stressing the importance of accessible healthcare for young adults, pointing out that many struggle to secure sufficient health insurance as they transition into adulthood.
As the conversation around insulin costs continues, advocates and lawmakers urge for swift action to make life-saving medications accessible to all, emphasizing that the health and stability of millions hang in the balance.
